Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,148
Completed, industry sponsors, Immunology and inflammation, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting139
- Completed1,148
1,148 trials
Showing 1 to 25, recently updated first.
Arcutis Biotherapeutics, Inc.Industry
NCT06998056 · 101 participants · Start Jun 9, 2025 · Primary completion Dec 4, 2025
Drug: ARQ-151 cream 0.05% · For: Atopic Dermatitis (Eczema)
Sites: Birmingham, Alabama; Bryant, Arkansas; Fountain Valley, California · 22 sites in all
SoligenixIndustry
NCT05442190 · 15 participants · Start Dec 14, 2022 · Primary completion Oct 22, 2025
Drug: Hypericin · For: Psoriasis; Plaque Psoriasis; Psoriasis Vulgaris
Sites: San Diego, California
- Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07251998 · 182 participants · Start Dec 22, 2025 · Primary completion Oct 30, 2026
Drug: ICP-332 Tablets; ICP-332 Tablets and 1 more · For: Plaque Psoriasis
Sites: Wuhu, China; Beijing, China; Chongqing, China · 22 sites in all
Aldeyra Therapeutics, Inc.Industry
NCT05717920 · 8 participants · Start Feb 15, 2023 · Primary completion Nov 21, 2023
Drug: ADX-629 (Open-label) · For: Atopic Dermatitis
Sites: Bexley, Ohio
- A Phase 2 Clinical Study of MIL62 in Systemic Lupus ErythematosusPivotal-lookingCompleted
Beijing Mabworks Biotech Co., Ltd.Industry
NCT05796206 · 123 participants · Start May 26, 2023 · Primary completion Nov 21, 2024
Drug: MIL62; placebo · For: Systemic Lupus Erythematosus
Sites: Beijing, China
- A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative ColitisCompleted
Accro Bioscience (Suzhou) LimitedIndustry
NCT07083193 · 25 participants · Start Jan 20, 2025 · Primary completion Apr 20, 2026
Drug: AC-101 · For: Ulcerative Colitis
Sites: Guangzhou, China
- A Phase 2 Study of HB0017 in Psoriasis PatientsPivotal-lookingCompleted
Huabo Biopharm Co., Ltd.Industry
NCT06592274 · 206 participants · Start Sep 30, 2024 · Primary completion Apr 30, 2025
Drug: HB0017; HB0017 and 1 more · For: Psoriasis (PsO)
Sites: Bengbu, China; Guangzhou, China; Changsha, China · 18 sites in all
- A Study With CIT-013 in RA PatientsCompleted
Citryll BVIndustry
NCT06567470 · 96 participants · Start Jul 29, 2025 · Primary completion Jul 2, 2026
Drug: CIT-013 low dose; CIT-013 high dose and 2 more · For: Rheumatoid Arthritis
Sites: Leuven, Belgium; Bamberg, Germany; Berlin, Germany · 20 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05798117 · 21 participants · Start Feb 28, 2023 · Primary completion Sep 24, 2026
Drug: YTB323 · For: Systemic Lupus Erythematosus; Lupus Nephritis
Sites: Clayton, Australia; Paris, France; Pessac, France · 10 sites in all
- A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UCPivotal-lookingCompleted
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Industry
NCT05611671 · 280 participants · Start Nov 21, 2022 · Primary completion Nov 28, 2024
Drug: MORF-057; Placebo · For: Inflammatory Bowel Diseases; Colitis, Ulcerative
Sites: Sun City, Arizona; Lancaster, California; Los Angeles, California · 102 sites in all
- Phase 2b Study of EVO756 in Adults With Atopic DermatitisPivotal-lookingCompleted
Evommune, Inc.Industry
NCT07150845 · 121 participants · Start Aug 26, 2025 · Primary completion Jul 23, 2026
Drug: EVO756; EVO756 and 2 more · For: Atopic Dermatitis
Sites: Phoenix, Arizona; Fremont, California; Los Angeles, California · 29 sites in all
Kangpu Biopharmaceuticals, Ltd.Industry
NCT04643067 · 64 participants · Start Jun 3, 2021 · Primary completion Jun 29, 2023
Drug: KPG-818 low dose in phase 1b; KPG-818 mid dose in phase 1b and 6 more · For: SLE; Drug
Sites: Anniston, Alabama; Birmingham, Alabama; Clearwater, Florida · 18 sites in all
- ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)Pivotal-lookingCompleted
Aclaris Therapeutics, Inc.Industry
NCT05279417 · 251 participants · Start Feb 1, 2022 · Primary completion Sep 5, 2023
Drug: ATI-450 50 mg oral tablet BID; Placebo oral tablet and 2 more · For: Rheumatoid Arthritis
Sites: El Cajon, California; Encino, California; La Jolla, California · 50 sites in all
- Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)Completed
Insmed IncorporatedIndustry
NCT06101823 · 50 participants · Start Nov 21, 2023 · Primary completion Sep 3, 2024
Drug: OpSCF; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Fountain Valley, California; Inglewood, California · 22 sites in all
- Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisPivotal-lookingCompleted
MoonLake Immunotherapeutics AGIndustry
NCT05640245 · 207 participants · Start Dec 13, 2022 · Primary completion Sep 5, 2023
Drug: Sonelokimab; Placebo and 1 more · For: Arthritis, Psoriatic
Sites: Rancho Mirage, California; Duncansville, Pennsylvania; Pleven, Bulgaria · 42 sites in all
Nanjing Immunophage Biotech Co., LtdIndustry
NCT06717815 · 24 participants · Start Feb 25, 2025 · Primary completion Jun 8, 2026
Drug: IPG11406 · For: Lupus Nephritis
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 17 sites in all
- A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)Pivotal-lookingCompleted
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT04996797 · 178 participants · Start Jul 14, 2021 · Primary completion Jun 6, 2023
Drug: Tulisokibart · For: Ulcerative Colitis
Sites: Mobile, Alabama; Phoenix, Arizona; Sun City, Arizona · 88 sites in all
Keymed Biosciences Co.LtdIndustry
NCT06116565 · 263 participants · Start Dec 21, 2023 · Primary completion Nov 26, 2025
Drug: CM310 · For: Atopic Dermatitis
Sites: Beijing, China
- A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisPivotal-lookingCompleted
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
NCT06602219 · 222 participants · Start Oct 25, 2024 · Primary completion Jul 24, 2025
Drug: LY4100511; Placebo · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Bryant, Arkansas; Beverly Hills, California · 58 sites in all
AbbVieAbbVie (ABBV)
NCT02782663 · 107 participants · Start May 18, 2016 · Primary completion Jul 18, 2025
Drug: ABT-494 · For: Crohn's Disease (CD)
Sites: La Jolla, California; San Francisco, California; Gainesville, Florida · 61 sites in all
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With PlaceboPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06015308 · 224 participants · Start Oct 6, 2023 · Primary completion Oct 1, 2025
Drug: Amlitelimab; Placebo and 2 more · For: Dermatitis Atopic
Sites: Birmingham, Alabama; Scottsdale, Arizona; Anaheim, California · 57 sites in all
- Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)Completed
Arcutis Biotherapeutics, Inc.Industry
NCT04746911 · 10 participants · Start Mar 1, 2021 · Primary completion May 11, 2022
Drug: ARQ-151 cream 0.3% · For: Psoriasis; Plaque Psoriasis
Sites: Mountain Brook, Alabama; Scottsdale, Arizona; Fountain Valley, California · 18 sites in all
- Safety and Efficacy of HPP737 in Adult Patients With Plaque PsoriasisPivotal-lookingCompleted
Newsoara Biopharma Co., Ltd.Industry
NCT07707141 · 123 participants · Start Mar 3, 2021 · Primary completion Dec 20, 2021
Drug: HPP737 6mg and placebo; HPP737 10mg and placebo and 2 more · For: Psoriasis
Sites: Beijing, China; Hangzhou, China; Jinan, China · 8 sites in all
NCT04718896 · 41 participants · Start Apr 6, 2021 · Primary completion Mar 12, 2025
Drug: bimekizumab · For: Moderate to Severe Plaque Psoriasis
Sites: Indianapolis, Indiana; Cypress, Texas; Calgary, Canada · 11 sites in all
- A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic DermatitisCompleted
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT07103174 · 60 participants · Start Jun 30, 2025 · Primary completion Mar 9, 2026
Drug: MG-K10/Placebo; MG-K10/Placebo · For: Atopic Dermatitis (AD)
Sites: Shanghai, China; Zhejiang, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.